Compare ADMA Biologics Inc (ADMA) vs Li Auto Inc (LI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Li Auto Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Li Auto Inc trades at $12.19 (market cap $11.78B). The key difference: Li Auto Inc is far larger — about 5.5× ADMA Biologics Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | LI | |
|---|---|---|
Market Cap | $2.13B | $11.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $31.80 |
52-Week Low | $7.60 | $11.74 |
Enterprise Value | $2.20B | $693.65M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Li Auto (LI) trades at $12.05, near its 52-week low, with a bearish technical outlook. Revenue declined to $112.31B in 2025, and net income fell to $1.12B, reflecting margin pressure. Analyst consensus is mixed with a $14.80 price target, but recent news highlights competitive headwinds and delivery growth of 30,895 vehicles in June 2026.
The stock faces near-term risks from intense EV competition and profitability challenges, but long-term recovery potential exists if L-series execution improves. Investors should weigh low valuation multiples against operational cash flow deficits and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
